Vivani Medical, Inc. (VANI) - רווח נקי למניה (EPS TTM)

Vivani Medical, Inc. (VANI) develops Inertia capsules for long-term drug delivery in diabetes treatment, replacing daily medications. The absence of revenue due to the clinical testing stage determines the annual net income per share trend, where the -0.33 level serves as a critical mark. The proprietary Medidur system provides a technological edge, creating significant barriers to entry for new market players.
VANI (Vivani): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Net income per share determines the actual return on equity by distributing the aggregate financial result among all security holders. The TTM annual earnings per share trend visualizes this vector, consolidating data from the last four quarters to smooth out seasonality. The current value of -0.33 reflects the final efficiency of operating activities. For Vivani Medical, Inc. (VANI), this metric depends directly on the costs of precision logistics for sterile implants. Supply chain optimization critically impacts the business's final margins.